News Related to Skin Cancer

Related coverage linked through entity extraction aliases.

C-POST Trial Shows Adjuvant Cemiplimab Cuts Risk in High-Risk Skin Cancer

Jun 14, 2026

The C-POST trial shows adjuvant cemiplimab improves disease-free survival in high-risk cutaneous squamous cell carcinoma, with a hazard ratio of 0.32. Meanwhile, an international Phase III study is testing cemiplimab before surgery in advanced cases. Cemiplimab is FDA-approved for advanced skin cancer but not yet for pre-surgical use.

Immunotherapy Expands to Earlier Cancer Stages Across Multiple Tumor Types

Mar 24, 2026

Immunotherapy is increasingly used in earlier cancer stages before or after surgery across seven tumor areas. Research shows neoadjuvant and adjuvant immunotherapy can reduce recurrence risk and improve immune recognition of tumor cells. However, challenges remain including side effects, costs, and determining which patients benefit most from earlier treatment.

New Zealand Proposes Expanded Access to Cancer Treatments

Mar 09, 2026

Pharmac has proposed expanding access to melanoma treatments and funding two new therapies for chronic lymphocytic leukaemia. Medical researchers also highlight that New Zealanders lack access to CAR T-cell therapy domestically.